BHST
BioHarvest Sciences Inc

306
Mkt Cap
$135.25M
Volume
164,048.00
52W High
$12.80
52W Low
$4.72
PE Ratio
-8.71
BHST Fundamentals
Price
$5.97
Prev Close
$6.34
Open
$6.30
50D MA
$9.56
Beta
-41.47
Avg. Volume
100,352.87
EPS (Annual)
-$0.7974
P/B
15.14
Rev/Employee
$289,517.24
Loading...
Loading...
News
all
press releases
BioHarvest Sciences (NASDAQ:BHST) Issues Earnings Results, Meets Expectations
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of 0.00% and -0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates
ABSCI CORP (ABSI) delivered earnings and revenue surprises of -5.26% and -79.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
BioHarvest Sciences Inc. - Common Stock Earnings Preview
read more...
Benzinga·11d ago
News Placeholder
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of +22.22% and -14.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -46.67% and -53.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +5.52% and +5.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Misses Revenue Estimates
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -36.36% and -2.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
The Joint (JYNT) delivered earnings and revenue surprises of +14.29% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +81.98% and +15.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest BHST News

View

Advertisement|Remove ads.

Advertisement|Remove ads.